Sam Konduros named president and CEO of S.C. Biotechnology … – Greenville News

Posted: Published on March 17th, 2017

This post was added by Dr P. Richardson

Sam Konduros(Photo: Provided)

Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization.

SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials.

Konduros is a currently a member of the SCBIO Board of Directors.

I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement.

Architecture and design firm adds new hire to Greenville office

Verizon looks to fill 100 positions at new telesales center in Greenville

Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts.

He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce.

Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. He is alsoa graduate of the Economic Development Institute at the University of Oklahoma.

Sams strengths in knowing the biotech sector and his deep experience in business and economic development were compelling, Erin Ford, chair of SCBIO, said in a statement. The board was won over by his vision for the growth of SCBIO.

Read or Share this story: http://grnol.co/2mJTIWt

Read more:
Sam Konduros named president and CEO of S.C. Biotechnology ... - Greenville News

Related Posts
This entry was posted in Biotechnology. Bookmark the permalink.

Comments are closed.